Designation of Ataluren (Translarna) as an orphan drug - Link Medical Products Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia are of acceptable quality, and their benefits outweigh any risks. This legislation establishes a framework for regulating therapeutic goods, including medicines, medical devices, and blood and blood components. One of the notable amendments to this Act, introduced in 2015, was the designation of Ataluren (TRANSLARNA) as an orphan drug. This designation was made under subregulation 16J(2) of the Therapeutic Goods Regulations 1990, aiming to address the specific needs of patients suffering from rare diseases such as Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. The objective of this designation is to encourage the development and availability of treatments for rare conditions that otherwise might not attract sufficient investment or research.

Scope and Application

The Therapeutic Goods Act 1989, as amended, provides the legislative framework for the regulation of therapeutic goods in Australia, encompassing medicines, medical devices, blood and blood components, and tissues. The Act applies to a wide array of entities including manufacturers, importers, and suppliers of therapeutic goods, as well as to individuals such as healthcare professionals who may be involved in the provision or administration of these goods. The legislation is administered by the Therapeutic Goods Administration (TGA), an agency of the Australian Department of Health, and it has a national reach across the Commonwealth of Australia. Notably, the Act includes provisions for the designation of orphan drugs, which are therapeutic goods intended for the treatment of rare medical conditions. In this context, the Act allows for the designation of specific drugs, such as Ataluren (TRANSLARNA), for particular conditions like Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. The geographic scope of the Act is national, impacting all states and territories within Australia. The application of the Act can be extended or restricted through subordinate instruments, such as regulations and guidelines, which provide further detail on specific requirements and procedures.

Key Provisions

The main operative sections of this Gazette, C2015G01204, pertain to the designation of Ataluren (TRANSLARNA) as an orphan drug for the treatment of a specific condition. According to section 16J of the Therapeutic Goods Regulations 1990, Ataluren (TRANSLARNA) has been designated as an orphan drug effective from 17 July 2015 (section 1). This designation is intended for patients with Duchenne muscular dystrophy caused by a nonsense mutation in the dystrophin gene (section 1). The form of the therapeutic good in this context is granules (section 1). The sponsor responsible for Ataluren (TRANSLARNA) is Link Medical Products Pty Ltd (section 1). The Therapeutic Goods Act 1989, as amended by this Gazette, imposes certain obligations and requirements on the parties involved. The designation of Ataluren (TRANSLARNA) as an orphan drug aims to provide incentives for the research, development, and availability of treatments for rare diseases. The sponsor, Link Medical Products Pty Ltd, is expected to comply with all relevant regulations and requirements set forth by the Therapeutic Goods Administration (section 16J). This includes ensuring the safety, efficacy, and quality of the therapeutic good through appropriate clinical trials, manufacturing processes, and labelling. Under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, there are potential offences, penalties, and consequences for non-compliance with the regulations. Violating the provisions related to the designation and marketing of orphan drugs can result in criminal or civil penalties. For instance, knowingly or recklessly supplying therapeutic goods that do not comply with the Act or the Regulations may result in a fine of up to $2,200,000 for a corporation or $440,000 for an individual, as well as imprisonment for up to five years (section 34(1) and 34(2) of the Act). Additionally, the Therapeutic Goods Administration has the authority to take enforcement actions, such as product recalls or court proceedings, to address non-compliance and protect public health and safety.